Ertugliflozin and Sitagliptin Co-initiation in Patients with Type 2 Diabetes: The VERTIS SITA Randomized Study

INTRODUCTION: Ertugliflozin is an oral sodium-glucose cotransporter 2 inhibitor that is being developed to treat type 2 diabetes mellitus (T2DM). This study assessed the efficacy and safety of co-initiation of ertugliflozin and sitagliptin compared with placebo in patients with T2DM inadequately con...

Volledige beschrijving

Bewaard in:
Bibliografische gegevens
Gepubliceerd in:Diabetes Ther
Hoofdauteurs: Miller, Sam, Krumins, Tania, Zhou, Haojin, Huyck, Susan, Johnson, Jeremy, Golm, Gregory, Terra, Steven G., Mancuso, James P., Engel, Samuel S., Lauring, Brett
Formaat: Artigo
Taal:Inglês
Gepubliceerd in: Springer Healthcare 2018
Onderwerpen:
Original Research
Online toegang:https://ncbi.nlm.nih.gov/pmc/articles/PMC5801244/
https://ncbi.nlm.nih.gov/pubmed/29313282
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s13300-017-0358-0
Tags: Voeg label toe
Geen labels, Wees de eerste die dit record labelt!

Gelijkaardige items